CLL Highlights from EHA 2026: Three Major Treatment Advances #CLL

Dr. Kerry Rogers from Ohio State University highlights three major CLL breakthroughs presented at EHA 2026.

THREE KEY UPDATES:

1. CLL14: 9-Year Follow-Up Results
Venetoclax + obinutuzumab remains effective after 9 years of follow-up. Now the approved standard first-line treatment. Results vary by genetics: deletion 17p patients have shorter remissions, while IGHM-mutated patients have longer remissions.

2. BTK Degraders: A New Drug Class
Unlike BTK inhibitors that block the protein, these drugs eliminate it entirely. This overcomes resistance mutations that develop in some CLL cells. Early results are promising, and longer follow-up data is being presented.

3. Zanibrutinib + Sonrotoclax Combination
A BTK inhibitor paired with a BCL2 inhibitor. Phase 3 trial results (randomized studies that often lead to approvals) are being presented. Already approved for mantle cell lymphoma, being studied in CLL.

WHY IT MATTERS:
CLL treatment continues to improve with longer remissions, better strategies to overcome drug resistance, and new drug combinations offering hope for better outcomes.

Learn more: https://linktr.ee/HealthTreeUniversity

TIMESTAMPS:
0:00 Introduction
0:13 Exciting Results at EHA 2026
0:21 #1: CLL14 Nine-Year Follow-Up
0:29 Venetoclax + Obinutuzumab Approval
0:46 Results by Genetics
1:02 Standard Treatment Success
1:10 #2: BTK Degraders (New Drug Class)
1:19 How BTK Inhibitors Work
1:27 How CLL Develops Resistance
1:37 How BTK Degraders Work
1:53 Early Phase Results
2:10 #3: Zanibrutinib + Sonrotoclax
2:18 Drug Combination Explained
2:36 Phase 3 Study (Path to Approval)
2:48 Exciting Data Being Presented

#CLL #EHA2026 #NewTreatments #ClinicalTrial #BTKInhibitor